CD274 and non-small cell lung carcinoma: Ground-breaking results of the phase III PACIFIC trial have led to the prompt establishment of cCRT followed by maintenance treatment with PD-L1 inhibitor durvalumab as a new tri-modal standard of care for unresectable stage III NSCLC.